

A large teal circle is positioned on the left side of the page, overlapping the bottom edge of the white circle. It serves as a background for the title text.

# **Teva's Position on Patient Safety**

Teva Pharmaceutical Industries Ltd. (hereinafter “Teva”), including all its directors, executives, employees and subsidiary and affiliated companies, is committed to patient safety. As the world’s leading manufacturer of generic medicines, and with a portfolio of approximately 3,000 medicines that reach nearly 200 million people each day, we uphold this commitment as a key responsibility to our patients and live it every day through our business practices.

At Teva, we embed robust safety measures across a product’s lifecycle—from manufacturing to delivery to physicians, pharmacies and patients around the world. Our global patient safety team monitors the safety of our medicines and, when necessary, mitigates risks and protects public health by working closely with regulatory authorities. The team consists of safety professionals, located in more than 45 countries, who collect and evaluate information about patients’ experiences with our products, including any adverse events. Teva’s commitment to patient safety is fundamental to delivering on our mission to be a global leader in generics and biopharmaceuticals, improving the lives of patients.

Our position on patient safety is part of our environmental, social and governance (ESG) strategy. It applies to all companies owned or operated by Teva, as well as our active pharmaceutical ingredient (API) suppliers and other supply chain partners.

## **Our Patient Safety Approach and Commitments**

---

**Leveraging technology and medical professionals to monitor medicines:** Our patient safety monitoring approach identifies potential new risks through digital systems and the medical expertise of trained physicians and pharmacists. These professionals initiate required risk mitigation efforts after assessing incoming reports and safety signals. A safety signal refers to information that suggests a new, potentially causal association (or a new aspect of a known association) between a Teva product and a potentially adverse event. Signals are assessed to determine if the potentially adverse event is related to a Teva product, or other products and/or patient-related factors, such as pre-existing illnesses, environmental and/or lifestyle hazards.

**Ensuring thorough review by health authorities and other independent groups:** Teva flags all case reports to applicable health authorities, per legal requirements, to enable independent review and assessment. When a new safety signal is identified, through the detection techniques mentioned above, our team ensures it is immediately addressed. Our operating procedures meet or exceed the legal requirements in all countries where we operate and are regularly reviewed by health authorities’ inspections, as well as specialized internal and external audits, including one evaluating good pharmacovigilance practices.

**Mitigating and communicating patient risk:** After identifying and assessing risk to patients, we work to communicate them transparently and mitigate future risks. This includes updating package inserts, informing healthcare providers and, when necessary, recalling a product. In addition, we encourage patients and caregivers to contact us or their physicians if they experience negative side effects that might be related to one of our medicines.

**Implementing mandatory employee trainings:** Our employees play a critical role in our patient safety efforts. We develop and implement mandatory patient safety trainings for all employees, which cover various communication protocols and reporting methods for sharing patient and product safety information. The first training is completed by employees within three months of joining Teva. Mandatory refresher trainings are implemented annually to ensure full compliance with company policies and standard operating procedures on patient safety as it relates to individual roles.

## **Governance Structure for Patient Safety**

---

The Global Head of Patient Safety reports via the Head of Medical Affairs & Pharmacovigilance to the Head of Research & Development, who is a member of Teva Executive Management. In addition, the Global Head of Patient Safety provides regular updates to the Compliance Committee of the Board of Directors on patient safety and/or compliance topics.

Our Global Head of Patient Safety leads our patient safety organization, ensuring patients come first in all decisions. The Global Head of Patient Safety also chairs our Corporate Safety Board (CSB), which serves as the highest level of safety governance at Teva.

Our CSB is made up of senior Teva leaders from Medical Affairs, Clinical, Regulatory, Legal and Quality. Collectively, they are responsible for making all high-impact decisions concerning patient safety. The CSB, as well as similarly comprised product safety groups (PSGs), regularly reviews and assesses the safety of Teva's products. They also evaluate global data collection system outputs—including product use data and scientific publications—to determine and initiate appropriate actions that optimize health benefits for patients, while mitigating potential risks. Teva's local safety officers are responsible for patient safety reporting and compliance with legal requirements in each country.

## **Application of this Position**

---

This position is endorsed by Teva's Board of Directors. We communicate this position to our employees and publicly on our website and share our progress in our annual ESG Progress Report.